A Drug With Promise

Trikafta targets the specific genetic mutations that are present in 90 per cent of cystic fibrosis (CF) cases and can drastically reduce or even eliminate the presence of mucus in the lungs, enabling easier breathing. Research suggests that Trikafta has the potential to increase the life expectancy of someone with CF by roughly a decade.

Since April this year, Trikafta has been available under the Pharmaceutical Benefits Scheme in Australia for patients aged 12 and older, costing a maximum of $42.50 per prescription. In New Zealand, the medication is available but not publicly funded and comes at an annual cost of NZ$330,000.

A campaign is currently underway in New Zealand to have Trikafta added to the list of governmentsubsidised medications.